guest ::
| Home > Publications database > Effect of Various Invitation Schemes on the Use of Fecal Immunochemical Tests for Colorectal Cancer Screening: Protocol for a Randomized Controlled Trial. |
| Home > Publications database > Effect of Various Invitation Schemes on the Use of Fecal Immunochemical Tests for Colorectal Cancer Screening: Protocol for a Randomized Controlled Trial. |
| Journal Article | DKFZ-2020-00750 |
; ; ;
2020
Toronto
This record in other databases: 
Please use a persistent id in citations: doi:10.2196/16413
Abstract: Fecal occult blood testing has been offered for many years in the German health care system, but participation rates have been notoriously low.The aim of this study is to evaluate the effect of various personal invitation schemes on the use of fecal immunochemical tests (FITs) in persons aged 50-54 years.This study consists of a three-armed randomized controlled trial: (1) arm A: an invitation letter from a health insurance plan including a FIT test kit, (2) arm B: an invitation letter from a health insurance plan including an offer to receive a free FIT test kit by mail upon easy-to-handle request (ie, by internet, fax, or reply mail), and (3) arm C: an information letter on an existing colonoscopy offer (ie, control). Within arms A and B, a random selection of 50% of the study population will receive reminder letters, the effects of which are to be evaluated in a substudy.A total of 17,532 persons aged 50-54 years in a statutory health insurance plan in the southwest of Germany-AOK Baden-Wuerttemberg-were sent an initial invitation, and 5825 reminder letters were sent out. The primary end point is FIT usage within 1 year from receipt of invitation or information letter. The main secondary end points include gender-specific FIT usage within 1 year, rates of positive test results, rates of colonoscopies following a positive test result, and detection rates of advanced neoplasms. The study was launched in September 2017. Data collection and workup were completed in fall 2019.This randomized controlled trial will provide important empirical evidence for enhancing colorectal cancer screening offers in the German health care system.German Clinical Trials Register (DRKS) DRKS00011858; https://bit.ly/2UBTIdt.DERR1-10.2196/16413.
; 
; 
; Clarivate Analytics Master Journal List ; DOAJ Seal ; Emerging Sources Citation Index ; PubMed Central ; Web of Science Core Collection
|
The record appears in these collections: |